REMARKS

Status of the Claims

Claims as Filed

Claims 1 to 9 are pending in the specification as filed.

Claims canceled, added and amended

In the instant preliminary amendment, Applicants canceled claims 6 and 7, amended claims 1 to 5 and 8, and added new claims 10 and 11. Thus, after entry of the instant amendment, claims 1 to 5 and 8 to 11 will be pending.

Support for the Claim Amendments

The specification sets forth an extensive description of the invention in the new and amended claims.

CONCLUSION

In view of the foregoing remarks and the instant amendment, it is believed that the all claims pending in this application (after entry of the instant amendment) are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If any additional necessary fee is required, the Commissioner is authorized to deduct such a fee from the undersigned's Deposit Account No. 06-1050. Please credit any overpayments to the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (858) 678-5070.

Respectfully submitted,

Date: Aug 31, 2001

Gregory P. Einhorn
Reg. No. 38,440

Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, California 92122
Telephone: (858) 678-5070
Facsimile: (858) 678-5099

10131279.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Applicant	: Nishino, N., et al.	Art Unit	: to be assigned
Serial No.	: to be assigned	Examiner	: to be assigned
Filed	: August 31, 2001		
Title	: NOVEL CYCLIC TETRAPEPTIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF		

In The Claims:

Claims 6 and 7 have been canceled.

Claim 1 has been amended as follows:

1. (Amended) A cyclic tetrapeptide derivative comprising a [represented by the following] general formula selected from the group consisting of (I), (I'), (I''), (I''') [or] and a pharmaceutically acceptable salt thereof:



(I)



(I')



(I")



(I''')

wherein each of R_{11}, R_{12}, R_{21} and R_{22} independently denotes hydrogen, a linear C_1-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached, or a branched C_3-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached; and

each of R_1, R_2 and R_3 independently denotes a linear C_1-C_5-alkylene group which may have a C_1-C_6 side chain, in which the side chain may form a condensed ring structure on the alkylene chain;

provided that at least one of R_{11}, R_{12}, R_{21} and R_{22} in general formula (I''') is a cyclohexyl methyl group.

2. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I), or a pharmaceutically acceptable salt thereof.

3. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I'), or a pharmaceutically acceptable salt thereof.

4. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I''), or a pharmaceutically acceptable salt thereof.

5. (Amended) The cyclic tetrapeptide derivative according to claim 1, comprising [which is represented by] said general formula (I'''), or a pharmaceutically acceptable salt thereof.

8. (Amended) A pharmaceutical composition comprising a [the] cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof [according to any one of claims] as set forth in claim 1 [to 5 as an active ingredient].

The following new claims have been added:

10. A method of inhibiting a histone deacetylase comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof as set forth in claim 1, thereby inhibiting a histone deacetylase inhibitor.

11. A method of promoting an expression of an MHC class I molecule comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof as set forth in claim 1, thereby promoting an expression of an MHC class I molecule.